Skip to content

Naoyuki Nogami

Université Paris-Sud

1 paper in the Anchorcite directory, published in 2017, cited 5,640 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Jean‐Charles Soria · 1 paper
  • Yuichiro Ohe · 1 paper
  • Johan Vansteenkiste · 1 paper
  • Thanyanan Reungwetwattana · 1 paper
  • Busayamas Chewaskulyong · 1 paper
  • Ki Hyeong Lee · 1 paper
  • Arunee Dechaphunkul · 1 paper
  • Fumio Imamura · 1 paper

Papers

  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations

    BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…

Metadata from OpenAlex (CC0).